Portola Pharmaceuticals' (NASDAQ: PTLA) stock recently jumped 45% on the news that it won its first FDA approval.
In this segment of Industry Focus: Healthcare, Motley Fool analyst Kristine Harjes and contributor Todd Campbell explain why investors might want to stick with the company rather than cash out now, and some important things to remember about investing in any biotech.
A full transcript follows the video.
Source: Fool.com